Immunohistochemical analysis of tissue sections of human triple-negative breast cancer showed that patients with a high expression of ACSS2 had a lower overall survival, and there was a strong correlation between ACSS2 levels and disease progression (Table 1). The gene discussed is ACSS2; the disease is triple-negative breast carcinoma.